Matthew M. Seavey, PhD, MBA., is the Vice President of Research & Technology Acquisition at NightHawk Biosciences, a fully integrated biopharmaceutical company focused on innovative approaches for medical countermeasures and battlefield medicine. Matthew also serves as Vice President of Business Development for Elusys Therapeutics, the developer and marketer of Anthim® (obiltoxaximab) for treatment of inhalation anthrax in combination with antibiotics and, or as a prophylaxis when alternative therapies are not available or are not appropriate. Prior to NightHawk/Elusys, Matthew served as Executive Director of Research at Heat Biologics, a biotechnology company focused on cancer immunotherapy and autoimmunity. As aninternational biopharma business and scientific leader with over 17 years in the pharmaceutical and biotech industry, his expertise encompasses various therapeutic areas, including oncology, inflammation, rare and infectious diseases, public health/vaccines, and medical countermeasures. Throughout his career, he has developed small and large molecules, as well as cell-therapy products, from discovery to market authorization. Matthew has a history of closing licensing deals, forming partnerships, and managing international business affairs. His passion centers on advancing human health through cutting-edge technology and improving access to innovative healthcare solutions, guided by principles of scientific integrity and data-driven decision-making. Matthew finds immense satisfaction in the creative process of establishing companies that blend innovative thinking with ethical application to enhance patients’ quality of life. In his free time, he’s a passionate travel and portrait photographer.